HER2/CD340 Protein, Rat (HEK293, His)

The HER2/CD340 protein is a multifunctional tyrosine kinase that is a component of the neuregulin receptor complex and regulates microtubule dynamics.Activated HER2/CD340 triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B on the cell membrane and promotes the binding of APC and CLASP2, which is critical for microtubule stability.HER2/CD340 Protein, Rat (HEK293, His) is the recombinant rat-derived HER2/CD340 protein, expressed by HEK293 , with C-10*His labeled tag.

HER2/CD340 protein, a multifaceted protein tyrosine kinase, serves as an essential component within various cell surface receptor complexes, requiring a coreceptor for ligand binding. Integral to neuregulin-receptor complexes, it collaborates with neuregulins, and GP30 emerges as a potential ligand for this receptor. Beyond its receptor roles, HER2/CD340 plays a pivotal role in regulating the outgrowth and stabilization of peripheral microtubules (MTs). Upon activation, the MEMO1-RHOA-DIAPH1 signaling pathway, triggered by ERBB2 activation, leads to GSK3B phosphorylation and subsequent inhibition at the cell membrane. This orchestrated inhibition prevents the phosphorylation of APC and CLASP2, facilitating their association with the cell membrane. The membrane-bound APC, in turn, facilitates the localization of MACF1 to the cell membrane, a critical step for microtubule capture and stabilization. Inside the nucleus, HER2/CD340 is involved in transcriptional regulation, associating with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activating its transcription. Additionally, it participates in the transcription of rRNA genes by RNA Pol I, enhancing protein synthesis and promoting cell growth. The multifaceted functions of HER2/CD340 underscore its central role in diverse cellular processes, from receptor signaling to microtubule dynamics and transcriptional regulation.

Measured by its ability to block anti-ErbB2 mediated inhibition of SK-BR-3 human breast cancer cell proliferation. The ED₅₀ this effect is ≤1.043 μg/mL in the presence of 0.6 µg/mL Trastuzmab, corresponding to a specific activity is ≥9.59×10² units/mg.

• 
  Measured by its ability to block anti-ErbB2 mediated inhibition of SK-BR-3 human breast cancer cell proliferation. The ED₅₀ for this effect is 1.043 μg/mL in the presence of 0.6 µg/mL Trastuzmab, corresponding to a specific activity is 9.59×10² units/mg.

Rat

HEK293

C-10*His

AAH61863 (M4-T656)

24337  [NCBI]

MELAAWCRWGFLLALLPPGIAGTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYVPANASLSFLQDIQEVQGYMLIAHNQVKRVPLQRLRIVRGTQLFEDKYALAVLDNRDPQDNVAASTPGRTPEGLRELQLRGLTEILKGGVLIRGNPQLCYQDMVLWKDVFRKNNQLAPVDIDTNRSRACPPCAPACKDNHCWGESPEDCQILTGTICTSGCARCKGRLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMHNPEGRYTFGASCVTTCPYNYLSTEVGSCTLVCPPNNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLRGARAITSDNVQEFDGCKKIFGSLAFLPESFDGDPSSGIAPLRPEQLQVFETLEEITGYLYISAWPDSLRDLSVFQNLRIIRGRILHDGAYSLTLQGLGIHSLGLRSLRELGSGLALIHRNAHLCFVHTVPWDQLFRNPHQALLHSGNRPEEDCGLEGLVCNSLCAHGHCWGPGPTQCVNCSHFLRGQECVEECRVWKGLPREYVSDKRCLPCHPECQPQNSSETCFGSEADQCAACAHYKDSSSCVARCPSGVKPDLSYMPIWKYPDEEGICQPCPINCTHSCVDLDERGCPAEQRASPVT

Approximately 91 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized powder.

Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.